Merck (MRK) Q3 Earnings and Revenues Beat Estimates
Merck (MRK) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $1.94 per share. This compares to earnings of $1.85 per share a year ago.
Merck results beat expectations on strong Keytruda, Gardasil and Covid drug growth
Merck's revenue and earnings beat expectations, and it hiked its sales forecast while lowering its profit outlook.
Merck 3rd-quarter profit tops expectations on COVID pill surprise
Merck & Co on Thursday reported higher-than-expected third-quarter sales and profit on surprisingly strong demand for its COVID-19 treatment, primarily in Japan.
Merck third-quarter results beat estimates, boosted by cancer drug and vaccine growth
Merck & Co. on Thursday reported third-quarter results that topped analysts' expectations, powered by growth in oncology and vaccines.
Is a Surprise Coming for Merck & Co. (MRK) This Earnings Season?
Merck & Co. (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Merck & Co. Inc. (MRK) Merck & Co. Announced Collaboration with Daiichi Sankyo and ESMO Investor Event (Transcript)
Merck & Co. Inc. (NYSE:MRK ) October 22, 2023 1:00 PM ET Company Participants Peter Dannenbaum - VP, IR Dr. Dean Li - President, Merck Research Labs Eliav Barr - CMO & Head of Global Clinical Devel...
Merck discontinues some cancer drug development with China's Sichuan Kelun
Chinese drugmaker Sichuan Kelun Pharmaceutical Co said on Monday that Merck & Co Inc was abandoning the joint development of two candidate cancer drugs which have yet to start clinical trials.
Merck (MRK) Inks Deal With Daiichi to Develop Cancer Drugs
Per the terms, Merck (MRK) and Daiichi Sankyo will develop and market three ADC drugs to treat multiple types of cancer. Following the execution, Merck will make an upfront payment of $4 billion.
Merck's Keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer
Merck & Co. MRK, -1.53% said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy achieved positive results as ...
Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Merck (MRK) stood at $100.43, denoting a -1.53% change from the preceding trading day.
Merck (MRK) Reports Next Week: Wall Street Expects Earnings Growth
Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck's (MRK) Keytruda Gets FDA Nod in Sixth NSCLC Indication
FDA has approved the expanded use of Merck's (MRK) Keytruda in certain patients with early-stage non-small cell lung cancer who can get their tumors removed surgically.
EU regulator backs Merck's viral infection drug
European health regulator backed Merck & Co's drug to treat a type of infection in adult kidney transplant recipients at high risk, the company said on Tuesday.
Merck's Keytruda gets U.S. FDA's nod for expanded use in lung cancer
The U.S. Food and Drug Administration on Monday approved the expanded use of Merck & Co's blockbuster immunotherapy Keytruda in early-stage patients with non-small cell lung cancer who can get thei...
CHMP Endorses Merck's (MRK) Keytruda Expansion in Gastric Cancer
If approved, Merck's (MRK) Keytruda will be approved for a second indication in advanced gastric or GEJ cancer.
Related Companies